Granuflo News

Dosing Errors Have Led to Another Lawsuit Against Fresenius

Fresenius is facing yet another lawsuit over GranuFlo, this one filed by a Louisiana man alleging harm was caused by alkali dosing errors tied to the product.

The new lawsuit involves several allegations including that:

  • Fresenius knew there were risks associated with Naturalyte and/or GranuFlo but hid that knowledge from not only the FDA, but also the public and the medical community.
  • Fresenius negligently and/or fraudulently represented that tests conducted on the products proved that the products were safe for their intended use.
  • Fresenius did not actually perform adequate testing to identify risks associated with Naturalyte or GranuFlo

The lawsuit centers on a Nov. 4, 2011 internal memo sent by Fresenius, that has been widely reported in the media. The memo, which appears very damaging, allegedly shows that Fresenius warned some of its medical directors and physicians about severe health risks tied to Naturalyte and GranuFlo. However, Fresenius did not warn the FDA about those same risks, which were reportedly identified in a case-control study on hemodialysis patients. According to the lawsuit, that November memo allegedly notes that the case-control study found “borderline elevated pre-dialysis bicarbonate levels and overt alkalosis arrest and sudden cardiac death.”

The lawsuit was filed by Ronnie Glasper, who was treated at a Fresenius Medical Care center in Louisiana. According to court documents, while undergoing dialysis, Glasper was prescribed either Naturalyte or GranuFlo. He later suffered a heart attack and stroke.

Glasper’s suit alleges that the memo was not sent to the Fresenius facility where he was treated or to the attending physician.

History of Problems
GranuFlo is a dry acid that is widely prescribed to evenly distribute elecrolytes during kidney dialysis. Fresenius is facing numerous lawsuits from patients alleging that they were harmed by GranuFlo and Naturalyte use. Eleven federal lawsuits were consolidated to MDL 2428 in the US District Court for the District of Massachusetts.

The health issues allegedly suffered by patients who used Naturalyte or GranuFlo include high blood serum bicarbonate levels, which can lead to death, cardiopulmonary arrest, cardiac arrhythmias, and stroke.

Contact an Attorney
If you or a loved one has suffered from GranuFlo dialysis treatment, you should contact an attorney immediately. Estey & Bomberger is nationally recognized for its success with product liability cases, including cases involving GranuFlo.



Granuflo News

FDA Warns Granuflo/NaturaLyte Manufacturer Again

The U.S. Food & Drug Administration (FDA) has issued another warning to GranuFlo/NaturaLyte manufacturer, Fresenius Medical Care. And the U.S. Judicial Panel on Multidistrict Litigation has decided to consolidate dozens of lawsuits against the firm.

The FDA warning, issued in March 2013, states that Fresenius failed to conduct adequate design verification studies of its electron beam (E-beam) dialyzers. The FDA also asserted that the company’s design did not meet specifications.

Dialysis is a process of filtering unwanted fluids from the blood. Patients with kidney malfunction require dialysis to remove toxins, such as urea, from their systems. Physicians use dialyzers to strain such waste products from the bloodstream and return clean blood to the body. Consequently, dialyzers are crucial to a successful dialysis procedure.

Prior recall

The FDA’s warning follows a 2012 Class 1 recall of GranuFlo and NaturaLyte, both concentrates used to treat acute and chronic renal (kidney) failure during dialysis.  Class I recalls are the most serious type of recall, used only when a product poses risks of  serious health consequences and/or death.  The recall drew attention to such risks, resulting from dosage errors.

Thousands of dialysis patients at risk

Fresenius operates more than 3,000 dialysis clinics throughout the United States, and an estimated 125,000 patients have been treated for kidney failure with GranuFlo and NaturalLyte. Low blood pressure, hypoxemia, cardiac arrhythmia and low potassium levels, which can lead to heart attack, cardiac arrest, stroke and sudden death, are all reported effects of GranuFlo and NaturaLyte dosage errors.

Company knew of hazards

An internal Fresenius memo, leaked to the FDA, revealed the company’s knowledge of these life-threatening complications. The 2011 memo, directed only to Fresenius clinicians, warned of more than 940 incidences of cardiac arrest among patients who received either GranuFlo or NaturaLyte while being treated at Fresenius clinics.

Dozens of lawsuits consolidated

Since the 2012 recall, approximately 40 lawsuits have been filed alleging that Fresenius failed to warn consumers and physicians at large of potential dosage risks, and, according to court documents, another 700 victims are waiting to file suit. In March 2013, the U.S. Judicial Panel on Multidistrict Litigation heard arguments in San Diego, about where to consolidate dozens of multi-state suits and decided on the District of Massachusetts.

If you or a loved one has suffered an injury due to a Fresnenius E-beam dialyzer or to use of either GranuFlo or NaturaLyte, you need to seek legal advice immediately.  Contact us for a free consultation. There is no charge to you until we win your case.